Cryoport (NASDAQ:CYRX - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Guggenheim in a report released on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. Guggenheim's price target suggests a potential upside of 85.87% from the stock's previous close.
Other research analysts have also recently issued reports about the stock. Roth Mkm reissued a "buy" rating and issued a $15.00 price objective on shares of Cryoport in a research note on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Cryoport in a research report on Thursday, April 10th. Finally, UBS Group boosted their target price on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $11.67.
Get Our Latest Report on CYRX
Cryoport Stock Performance
Shares of NASDAQ:CYRX traded down $0.17 on Wednesday, reaching $5.38. 167,569 shares of the company's stock were exchanged, compared to its average volume of 543,125. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport has a twelve month low of $4.58 and a twelve month high of $17.41. The company has a fifty day moving average of $5.99 and a 200-day moving average of $7.00. The company has a market capitalization of $268.52 million, a price-to-earnings ratio of -1.59 and a beta of 1.81.
Cryoport (NASDAQ:CYRX - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. On average, research analysts predict that Cryoport will post -0.99 EPS for the current fiscal year.
Insider Transactions at Cryoport
In other news, CEO Jerrell Shelton sold 4,620 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 19,830 shares of company stock worth $118,353. Company insiders own 10.10% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its holdings in Cryoport by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock valued at $3,012,000 after buying an additional 1,512 shares during the period. Rhumbline Advisers grew its stake in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after purchasing an additional 1,764 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its holdings in Cryoport by 148.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Nebula Research & Development LLC boosted its holdings in shares of Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after buying an additional 2,207 shares in the last quarter. Finally, Penbrook Management LLC boosted its holdings in shares of Cryoport by 6.0% during the 4th quarter. Penbrook Management LLC now owns 52,570 shares of the company's stock worth $409,000 after buying an additional 2,975 shares in the last quarter. Institutional investors own 92.90% of the company's stock.
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Stories
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
